Screener / SEC EDGAR /CIK 0001824920 /10-K filed Feb 25, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Technology · IT Services

IonQ, Inc. IONQ

Compare with peers Embed
SEC comment letters, last 20 years

1 review of IONQ's filings by SEC staff

UPLOAD and CORRESP
Reviews 1 latest letter Apr 27, 2021
Questions asked 25 each answered in the company's own letter
No closing letter 1 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 3 UPLOAD
  2. 2. Questions in them 25 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 0 of 1 closing letter

Form S-4

2021-04-27 to 2021-10-20 · 25 questions · 3 letters from the SEC, 5 from the company
No closing letter
AcquisitionsCritical estimatesRevenueRisk factorsResults discussion (MD&A)
What vote is required to approve the proposals presented at the Special Meeting?, page 6
SEC asked (1)
In light of the vote requirement for approval of the proposals, please revise here or elsewhere to discuss how the voting requirement and the voting and support agreements make it more likely the business combination will be approved.
Rest of the question

For example, discuss the percentage of shares not subject to the voting and support agreements that would be required to approve the business combination proposal if only a quorum of dMY Technology Group, Inc. III shareholders are present.

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 7 of Amendment No. 1.
Read in the reply
Summary, page 17
SEC asked (2)
We note the redemption feature of the warrants whereby the company may redeem the public warrants for Class A ordinary shares based upon the “fair market value” of the Class A ordinary shares. In the summary section, disclose this redemption feature.
Rest of the question

Revise the risk factor on page 75 to focus on this redemption feature triggered by a trading price of $10.00 (rather than the $18.00 feature) and highlight that (1) the trading price is less than the exercise price of the warrants ($11.50) and (2) may result in investors having to exercise the warrants at a time when they are out-of-the-money or receive nominal consideration from the company for them.

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 37 and 76 of Amendment No. 1.
Read in the reply
IonQ Stockholder Support Agreement, page 20
SEC asked (3)
We note your disclosure that you entered into a stockholder support agreement with certain IonQ stockholders. Please revise to clarify the aggregate voting power those stockholders hold.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosures on pages 20, 133 and 237 of Amendment No. 1 to include the aggregate voting power of the IonQ stockholders that entered into the stockholder support agreement.
Read in the reply
Risk Factors · IonQ systems depend on the use of a particular isotope of an atomic element..., page 52
SEC asked (4)
You state that IonQ is currently reliant on a single supplier of isotopically enriched materials and that there are limited suppliers for such resources. Please identify the supplier and provide a description of any agreements with this supplier including termination provisions.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 53 of Amendment No. 1 to indicate that IonQ currently purchases its isotopically enriched materials through the National Isotope Development Center managed by the U.S. Department of Energy Isotope Program, and that IonQ does not have any supplier agreements to acquire such materials.
Read in the reply
IonQ may rely heavily on future collaborative partners, page 52
SEC asked (5)
You state that IonQ has entered into strategic partnerships to develop and commercialize IonQ's current and future research and development programs with other companies. To the extent material, please disclose the terms of those agreements for strategic partnerships including obligations of the parties and financial arrangements.
IONQ answered
The Company respectfully advises the Staff that IonQ does not view any of the strategic partnerships to develop and commercialize its current and future research and development programs as material to IonQ’s business.
Read in the reply
The Business Combination · Terms of the Merger, page 98
SEC asked (6)
We note that you determined the equity valuation of IonQ to be $1.275 billion. Given the limited revenues and operating history of IonQ, please provide a more detailed discussion regarding the underlying assumptions and information used in determining this enterprise value.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 104 of Amendment No. 1.
Read in the reply
Certain Projected Financial Information, page 105
SEC asked (7)
We note that the disclosed prospective financial information for IonQ, Inc. is a summary of projections provided by IonQ to dMY. Tell us whether any other information was provided to dMY to support the projections. If so, disclose the material estimates and hypothetical assumptions upon which they are based. Regarding the customer warrant disclosed in Note 9.
Rest of the question

"Warrant Transaction Agreement" on page F-21, please advise as to the materiality of the revenue offset if such revenues are reflected in your projections.

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosures on pages 107 and 108 of Amendment No. 1 to reflect the additional estimates and assumptions made by IonQ with respect to industry performance and competition, general business, economic, market and financial conditions and matters specific to its business.

The Company respectfully advises the Staff that the revenue offset from the warrant disclosed in Note 9. “Warrant Transaction

Agreement” on page F-21 was not reflected in the IonQ projections.
Read in the reply
Comparative Historical and Unaudited Pro Forma Per Share Data, page 145
SEC asked (8)
We note you currently provide the actual closing market prices per share and no pro forma per share data. Please clarify if you intend to provide pro forma information giving effect to the Business Combination, assuming different redemption scenarios.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 151 of Amendment No. 1 to reference the pro forma information giving effect to the Business Combination, assuming different redemption scenarios included on page 148 of Amendment No. 1 under the title “Comparative Share Information.”
Read in the reply
Agreements with the University of Maryland and Duke University · Exclusive License Agreement, page 178
SEC asked (9)
We note your disclosure that the terms of the exclusive license agreement with Duke and the University of Maryland include that the company must make commercially reasonable efforts to meet "such other milestones that IonQ may specify in a development plan provided by IonQ to the universities..." Please revise to provide a discussion of the additional milestones the Company has specified in its development plan
Rest of the question

provided to the universities.

IONQ answered
The Company respectfully advises the Staff that IonQ has not included any additional milestones in any development plan provided to the universities, and further, that IonQ no longer has any obligation to submit development plans to the universities. The Company has revised the disclosure on page 185 of Amendment No. 1 to disclose this information.
Read in the reply
Information About IonQ · Competition, page 180
SEC asked (10)
Please revise to provide additional disclosure regarding competition in the trapped ion quantum competing space, specifically addressing how "IonQ’s processor architecture, system design and implementation and its strategies to scale" are superior to your competition.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 187 of Amendment No. 1 to address how IonQ’s processor architecture, system design and implementation and strategies to scale are superior to its competition.

Proposal No.
Read in the reply
Proposal No. 3 - The Charter Proposal · Reason for the Amendment, page 233
SEC asked (11)
Please balance your discussion of the reasons for adopting a classified board structure, removing the ability to act by written consent, exclusive forum provision and requiring the approval of two-thirds of the voting power to make certain amendments to your charter and bylaws with a discussion of the disadvantages to stockholders of these proposals
IONQ answered
The Company respectfully advises the Staff that the Company’s existing certificate of incorporation (the “Current Charter”) and bylaws reflect both a classified board structure and an exclusive forum provision. Accordingly, the Charter Proposal does not reflect these as amendments to the Current

Charter. The Company has revised the disclosure on page 244 of Amendment No. 1 to reflect this information. The Company has also revised the disclosures on pages 244 and 245 of Amendment No.
Rest of the answer

1 to reflect the disadvantages to stockholders of removing the ability to act by written consent and requiring the approval of two-thirds of the voting power to make certain amendments to the Proposed Charter and amended and restated bylaws.

Read in the reply
Note 10. Stock-Based Compensation, page F-22
SEC asked (12)
Please provide us with a breakdown of all equity awards granted to date in fiscal 2020 and leading up to the filing of the Form S-4, including the fair value of the underlying common stock used to value such awards as determined by your board of directors.
Rest of the question

To the extent there were any significant fluctuations in the fair values from period-to-period, please describe for us the factors that contributed to these fluctuations, including any intervening events within the Company or changes in your valuation assumptions or methodology. Compare the most recent valuations for options granted to the fair value of the shares of commons stock as determined by the conversion ratio described in the Business Combination Agreement. In addition, please include Equity-Based Compensation and Common Stock Valuations within your Critical Accounting Policies.

IONQ answered
Stock

Option Grants

Set forth in the table below are the stock options granted by IonQ during 2020 and through the filing of the Form S-4, including the fair value of the underlying shares of common stock used to value such awards at the grant date.

Grant Date

Number of

Shares of

Common Stock

Underlying

Stock Options

Granted (#)

Exercise Price

Per Share of

Common

($)

Deemed Fair

Value Per

Share of for

Financial

Accounting

Purposes

Applicable 409A

Valuation Report

January 8, 2020

340,578

1.88

2.00

October 2019

February 11, 2020

113,509

2.05

April 16,
Rest of the answer

2020

240,808

2.13

August 5, 2020

170,117

2.28

September 10, 2020

29,295

2.44

November 3, 2020

1,429,969

2.79

5.19

October 2020

November 17, 2020

115,000

6.59

January 12, 2021

258,815

9.68

16.56

December 2020

January 20, 2021

200,000

18.77

February 9, 2021

25,000

24.27

February 19, 2021

667,377

27.03

March 4, 2021

452,517

30.61

Common Stock Valuation Methodologies

As there has been no public market for IonQ’s common stock to date, the estimated fair value of its common stock has been determined by

IonQ’s board of directors (the “IonQ Board”), as of the date of each option grant, with input from IonQ’s management, considering the most recent third-party valuation of its common stock, as well as the IonQ Board’s assessment of additional objective and subjective factors that the IonQ Board believed were relevant and which may have changed from the date of the most recent valuation date through the grant date. The IonQ Board considered various objective and subjective factors to determine the fair value of the common stock as of each grant date, as set forth on pages 201 and 202 of Amendment No. 1, including:

• contemporaneous valuations performed at periodic intervals by independent third-party specialists;

IonQ’s actual operating results and financial performance;

IonQ’s current business conditions and projections;

IonQ’s progress on research and development efforts;

stage of development;

the prices, preferences and privileges of shares of IonQ’s convertible preferred stock relative to shares of

IonQ’s common stock;

likelihood of achieving a liquidity event for the underlying equity instruments, such as a business combination, given prevailing market conditions;

lack of marketability of IonQ’s common stock; and macroeconomic conditions.

The third-party valuations of IonQ’s common stock that the IonQ Board considered in making its determinations were prepared in accordance with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “Practice Guide”), which prescribes several valuation approaches for determining the value of an enterprise, such as the cost, market and income approaches, and various methodologies for allocating the value of an enterprise to its capital structure and specifically the common stock.

For each valuation report listed in the table above and for the March 2021 Valuation Report described below, IonQ made a determination of enterprise value using the market approach. The asset and income approaches were both considered, however, neither approach was deemed appropriate. In deriving enterprise value using the market approach, IonQ used the Back-Solve Method and the transaction price of secondary transactions in IonQ’s capital stock. The Back-Solve Method infers market value implied by a financing transaction on an arms-length basis. Additionally, for those valuations that were not performed in close proximity to a secondary transaction, IonQ determined the enterprise value by adjusting the transaction price of secondary transactions for the value of IonQ’s research and development efforts in the intervening period based on a return on cost method. Finally, the market approach began to incorporate the potential business combination as this exit strategy became more probable.

In accordance with the Practice Guide, IonQ considered the following methods for allocating the enterprise value across its classes of capital stock to determine the fair value of its common stock at each valuation date.

Option Pricing Method (“OPM”). The OPM estimates the value of the common equity of IonQ using the various inputs in the Black-Scholes option pricing model. The OPM treats the rights of the holders of common stock as equivalent to that of call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of IonQ’s preferred stock, as well as their rights to participation, and the stock prices of the outstanding options. Thus, the value of the common stock can be determined by estimating the value of its portion of each of these call option rights. Under this method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the liquidation preference at the time of a liquidity event, such as a merger or sale.

Given the common stock represents a non-marketable equity interest in a private enterprise, an adjustment to the preliminary value estimates had to be made to account for the lack of liquidity that a stockholder experiences. This adjustment is commonly referred to as a discount for lack of marketability (“DLOM”).

Probability-Weighted Expected Return Method (“PWERM”). The PWERM employs additional information not used in the OPM, including various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios, such as the sale of IonQ to a special purpose acquisition company

(“SPAC”), as well as the probability of remaining a private company. The PWERM is typically used when the range of possible future outcomes and liquidity events for an enterprise, including a business combination such as a merger of

IonQ and a SPAC, has narrowed, giving the enterprise a higher degree of confidence in the achievement of a particular outcome. As such, the PWERM can give more weight to the likely liquidity scenarios as compared to the normative distribution of the outcomes in the OPM.

For financial reporting purposes, and as further described below, IonQ also retrospectively assessed the deemed fair value of its common stock used for calculating and recording stock-based compensation charges after considering the fair value reflected on subsequent valuation reports and other facts and circumstances on the date of grant.

IonQ used a linear interpolation method to estimate the fair value between valuation dates. IonQ believes that the linear interpolation methodology provides the most reasonable basis for the valuation of its common stock because IonQ did not identify any significant events that occurred during the intervening periods that would have caused a material change in fair value.

2020 Stock Awards and Valuations

October 2019 Valuation

As set forth in the table above, from January 8, 2020 to September 10, 2020, IonQ granted options to purchase an aggregate of 894,307 shares of common stock at an exercise price of $1.88 per share. The IonQ Board determined the fair value of the stock as of each grant date to be $1.88 per share based on a number of factors, including IonQ’s most recently completed valuation, dated October 11, 2019 (the “October 2019 Valuation”), which determined the fair value of the stock was $1.88 per share utilizing the OPM. The October 2019 Valuation was performed concurrently with IonQ’s Series B-1 preferred stock financing, which was the last financing transaction prior to the business combination. From August 2019 through November 2019, IonQ issued 11,166,941 shares of Series B-1 preferred stock at $5.5757 per share to various new third-party investors. The IonQ Board determined that no significant events occurred subsequent to the October 2019 Valuation and the respective grant dates of such awards which would warrant a change in the fair value of the common stock.

October 2020 Valuation

In September 2020, the Board began holding preliminary discussions regarding potential exit strategies, including a business combination with a

SPAC. IonQ then initiated discussions with various SPACs, as discussed in the section titled “The Business Combination” in Amendment No. 1. As a result of these discussions, IonQ’s management and a third-party valuation firm performed a valuation of IonQ’s common stock as of October 10, 2020 (the “October 2020 Valuation”).

For the October 2020 Valuation, IonQ utilized a PWERM relying on (1) the OPM method to value a continued operations scenario where IonQ remained a private entity (the “Stay Private Scenario”) and (2) a transaction scenario that reflected a merger with a SPAC (the “Transaction Scenario”). To assess the enterprise value under the Stay Private Scenario, IonQ utilized a market approach using an adjusted back-solve method to determine IonQ’s enterprise value, which consisted of using the October 2019 back-solve method valuation and adjusting for the increase in enterprise value based on the advancement of IonQ’s quantum computing technology between intervening dates. After determining the enterprise value, the OPM was used to allocate the enterprise value to IonQ’s capital stock, including IonQ’s common stock. IonQ began incorporating the probability of a liquidity event into its methodology for determining the fair value of its common stock based on discussions with certain new investors who were willing to participate in a private placement of common stock based on a pre-money equity value of $500 million. The resulting fair value of $2.79 per share was derived based on a weighted value assigned to the Stay Private Scenario and Transaction Scenario of 95% and 5% and applying a 35% and 15% DLOM, respectively. IonQ assigned a 5% probability to the Transaction Scenario because prior to the October 2020 Valuation, IonQ was in the exploratory stages of considering a Transaction Scenario and the IonQ Board had only met once regarding a potential introduction to dMY. While IonQ’s management determined there was a greater than 0% probability that a business combination would occur, the IonQ Board had not yet determined that it was the appropriate path, but rather was of the opinion that a Stay Private Scenario was significantly more probable. Given the IonQ Board’s view, the significant hurdles that existed, and the preliminary nature of the discussions, 5% was deemed to be an appropriate probability.

IonQ also considered the following significant events to determine the fair value of its common stock:

on June 30, 2020, IonQ publicly announced the availability of its hardware on the AWS QC Service, which signaled the possibility of future commercial viability of IonQ’s product; and between October 2019 and October 2020, IonQ completed development of its fifth quantum computer and began development of its next generation of quantum computers.

As set forth in the table above, on November 3, 2020 and

November 17, 2020, IonQ granted options to purchase 1,429,969 and 115,000 shares of common stock, respectively, at an exercise price of $2.79 per share. The IonQ Board determined the fair value of the stock as of each grant date based on a number of factors, including the October 2020 Valuation, and determined there were no significant events that transpired between October 2020 and the grant date of the awards that warranted a change in the fair value of its common stock. .

December 2020 Valuation

On December 11, 2020, IonQ and dMY entered into a letter of intent (the “Letter of Intent”) for the proposed business combination with pre-money equity value for IonQ of $1.275 billion. IonQ’s management and a third-party valuation firm subsequently performed a valuation of IonQ’s common stock as of

December 18, 2020 (the “December 2020 Valuation”).

IonQ continued to utilize a PWERM relying on a Stay Private

Scenario and Transaction Scenario. To assess the enterprise value under the Stay Private Scenario, IonQ utilized a market approach using an adjusted back-solve method to determine IonQ’s enterprise value which consisted of using a back-solve method valuation and adjusting for the increase in enterprise value from October 2019 based on the advancement of IonQ’s quantum computing technology between the intervening dates. After determining the enterprise value, the OPM was used to allocate the enterprise value to IonQ’s capital stock. The Transaction Scenario utilized the Letter of Intent and pre-money equity value of $1.275 billion. The resulting fair value of $9.68 per share was derived based on a weighted value assigned to the Stay Private Scenario and Transaction Scenario of 75% and 25% with a DLOM of 35% and 8%, respectively. IonQ increased the Transaction Scenario probability from the October 2020 Valuation primarily due to continued progress on pursuing the proposed business combination, which included the hiring of advisors, developing financial models, making significant progress on due diligence efforts and negotiating transaction pricing. However, the Letter of Intent was non-binding and subject to several conditions that would need to be met prior to consummation of the business combination. The weightings also reflect the following factors:

due diligence by dMY was ongoing;

IonQ’s lack of several key significant management hires that would be critical to the successful completion of the business combination, including a general counsel and chief financial officer, as well as additional financial reporting and accounting personnel;

the initial audits of IonQ’s 2019 and 2020 financial statements had not been completed;

the Merger Agreement had not yet been executed and the Registration Statement on Form S-4 had not yet been filed; and the negotiation of the private placement of common stock to close concurrent with the closing of the business combination, estimated at $300 million, had not been initiated and initial meetings with potential investors did not begin until January 2021.

Reassessment of 2020 Awards

With the benefit of hindsight, and for financial reporting purposes to calculate and record stock-based compensation charges, IonQ retrospectively assessed the fair value of its common stock in connection with its equity awards during the year ended December 31, 2020 using a linear interpolation methodology between respective valuation dates. IonQ respectfully submits that linear interpolation provides the most reasonable basis for the valuation of its common stock during 2020 because IonQ did not identify any individual significant events that occurred during the period between valuation dates that would have caused a material change in fair value.

2021 Stock Awards and Valuations

As set forth in the table above, between January 12, 2021 and March 4, 2021, IonQ granted options to purchase an aggregate of

1,603,709 shares of common stock at an exercise price of $9.68 per share. The IonQ Board determined the fair value of the stock as of the each grant date based on a number of factors, including the December 2020 Valuation, and determined there were no significant events that transpired between the December 2020 Valuation and such grant dates that warranted a change in the fair value of its common stock.

March 2021 Valuation

On March 7, 2021, IonQ signed the definitive merger agreement with dMY with a pre-money equity value of $1.275 billion. IonQ’s management and a third-party valuation firm performed a valuation of IonQ’s common stock as of March 8, 2021 (the “March 2021 Valuation”).

For the March 2021 Valuation, IonQ continued to utilize a PWERM relying on a Stay Private Scenario and Transaction Scenario. To assess the enterprise value under the Stay Private Scenario, IonQ utilized the market approach using an adjusted back-solve method to determine IonQ’s enterprise value which consisted of using the October 2019 back-solve method valuation and adjusting for the increase in enterprise value based on the advancement of IonQ’s quantum computing technology between the intervening dates. After determining enterprise value, the OPM was used to allocate the enterprise value of IonQ to IonQ’s capital stock, including IonQ’s common stock. The Transaction Scenario was based on the pre-money equity value of $1.275 billion as contemplated by the business combination. The resulting fair value of

$31.71 per share was derived based on a weighted value assigned to the Stay Private Scenario and Transaction Scenario of 15% and 85%, and applying DLOMs of 35% and 9%, respectively. IonQ believes that the following significant factors contributed to the increase in the probability of Transaction Scenario between the December 2020 Valuation and the March 2021 Valuation:

hiring of key personnel such as a general counsel and a chief financial officer;

completion of the financial statement audits for the years ended December 31, 2019 and 2020;

execution of the Merger Agreement between IonQ and dMY;

finalization of $300 million in subscription agreements for the private placement to close concurrently with the closing of the business combination; and completion of due diligence on IonQ by dMY.

IonQ continued to make progress on the business combination throughout the quarter, which culminated in the approval of the Merger Agreement by the dMY board of directors and the IonQ Board on March 7, 2021. However, as of March 8, 2021, there continued to exist several precedents to the closing of the business combination, such as:

completion of IonQ’s financial statements for the three months ended March 31, 2021, and any subsequent quarters as may be required by the Registration Statement on Form S-4;

receipt of the requisite vote at the special meeting of dMY stockholders; and market risks, including continued market acceptance and appetite for SPAC transactions.

In consideration of the above, the Transaction Scenario was weighted at 85% with a 9% DLOM, and the fair value of IonQ’s common stock was determined to be $31.71 per share.

IonQ respectfully advises the Staff that it has not issued any additional stock awards since

March 4, 2021.

Reassessment of 2021 Awards

As a result of the March 2021 Valuation, IonQ retrospectively assessed the fair value of IonQ’s common stock in connection with the 2021

Awards using a linear interpolation and deemed fair value per share for financial accounting purposes ranging between $16.56 and $30.61. Significant changes between the December 2020 Valuation and the March 2021 Valuation resulted from the increase in probability of the Transaction Scenario from 25% to 85%. IonQ believes that the linear interpolation provides the most reasonable basis for the valuation of its common stock because IonQ did not identify any significant events that occurred during the period between valuation dates that would have caused a material change in fair value. Rather, the increase in probability of the Transaction Scenario resulted from the incremental progress on the various factors highlighted above between

December 2020 and March 2021 that culminated in the approval of the Merger Agreement by the dMY board of directors.

Business

Combination Implied Fair Value

On March 8, 2021, the Company and IonQ announced the proposed business combination of the companies which had a pre-money equity value for IonQ of $1.275 billion. The implied fair value of the shares of IonQ common stock as determined by the exchange ratio in the business combination is $41.30 per share.

As disclosed in IonQ’s investor presentation filed by the Company on a Current Report on Form 8-K on March 8, 2021, the IonQ equity value applies a range of 10.0x to 15.0x revenue multiple to IonQ’s 2026 estimated revenue to arrive at an implied future enterprise value range. This range was then discounted five years at a 20% discount rate to arrive at an implied discounted enterprise value range. IonQ utilized 2026 projected financials based on the expected IonQ roadmap for revenue growth and the inflection point in quantum computing maturity.

While the valuations of IonQ’s common stock for financial reporting purposes were determined in accordance with the guidelines set forth in the Practice Guide, IonQ’s determination of fair value per share in connection with the proposed business combination was based on 2026 estimated revenue and a revenue multiple, and discounted back to 2021.

IonQ respectfully submits that the process the IonQ Board used to determine the fair value of its common stock was appropriate and represents the fair value of its common stock on such date, based upon all information available to the IonQ Board on such date as discussed above. However, with the benefit of hindsight, for financial reporting purposes, IonQ has re-assessed the fair value of its common stock for purposes of calculating and recording stock-based compensation charges utilizing a linear interpolation between the dates of its valuations. As indicated above,

IonQ respectfully submits that linear interpolation provides the most reasonable basis for the valuation of its common stock during 2020 and to date in 2021 because IonQ did not identify any individual significant events that occurred during the period between valuation dates that would have caused a material change in fair value. In addition, IonQ believes that the fair value of its common stock as determined in accordance with the Practice Guide as of March 8, 2021 is the appropriate value by which to measure the fair value of its common stock versus the implied value of its common stock as determined for purposes of the business combination due the inherent uncertainty of completing the business combination.

Critical Accounting Policies

Please refer to page 201 of Amendment No. 1 for a revised description of Stock-Based Compensation and Equity Valuations within IonQ’s

Critical Accounting Policies.

Read in the reply
Note 6. Stockholders' Equity, page F-44
SEC asked (13)
For your public and private placement warrants, please explain how the warrant terms and accounting literature support your balance sheet classification over the reported periods. Please refer to the guidance in ASC 815-40 and the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies on April 12, 2021.
IONQ answered
In response to the Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies on April 12, 2021, the Company reassessed its accounting for its public and private placement warrants. Based on this reassessment, management determined that the public and private placement warrants should be classified as liabilities measured at fair value upon issuance, with subsequent changes in fair value reported in the Statement of Operations each reporting period.
Rest of the answer

The previously issued financial statements as of December 31, 2020 and for the period from September 14, 2020 (inception) through December 31, 2020 have been restated and are presented in Amendment No. 1.

****************************

We hope that the Company’s responses above adequately addresses the Staff’s comments. If the Staff has any questions or requires any additional information, please do not hesitate to contact Adam J. Brenneman at Cleary Gottlieb Steen & Hamilton LLP at (212) 225-2000.

Read in the reply
SEC asked (1)
Please disclose the sponsor and its affiliates’ total potential ownership interest in the combined company, assuming exercise and conversion of all securities. "Will dMY obtain new financing in connection with the Business Combination?", page 5
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 5 and 6 of Amendment No. 2.
Read in the reply
SEC asked (2)
Please highlight material differences in the terms and price of securities issued at the time of the IPO as compared to private placements contemplated at the time of the business combination. Disclose if the SPAC’s sponsors, directors, officers or their affiliates will participate in the private placement.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 6 of Amendment No. 2.
Read in the reply
"What interests does the Sponsor and dMY's officers and directors have in the Business Combination?", page 8
SEC asked (3)
Please clarify if the sponsor and its affiliates can earn a positive rate of return on their investment, even if other SPAC shareholders experience a negative rate of return in the post-business combination company.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 9, 32, 66, 93 and 112 of Amendment

No. 2.
Read in the reply
"What interests does the Sponsor and dMY's officers and directors have in the Business Combination?", page 8
SEC asked (4)
Please quantify the aggregate dollar amount and describe the nature of what the sponsor and its affiliates have at risk that depends on completion of a business combination. Include the current value of securities held, loans extended, fees due, and out-of-pocket expenses for which the sponsor and its affiliates are awaiting reimbursement.
Rest of the question

Provide similar disclosure for the company’s officers and directors, if material. "Can our Initial Stockholders redeem their Founder Shares in connection with consummation of the Business Combination?", page 10

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 8, 30, 64, 91, 110 of Amendment

“Can our Initial Stockholders redeem their Founder Shares in connection with consummation of the Business Combination?”, page
Read in the reply
"What interests does the Sponsor and dMY's officers and directors have in the Business Combination?", page 8
SEC asked (5)
We note that certain shareholders agreed to waive their redemption rights. Please describe any consideration provided in exchange for this agreement.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 11 of Amendment No. 2.
Read in the reply
Summary, page 17
SEC asked (6)
In an appropriate location in this section, please revise your disclosure to show the potential impact of redemptions on the per share value of the shares owned by nonredeeming shareholders by including a sensitivity analysis showing a range of redemption scenarios, including minimum, maximum and interim redemption levels.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 5 and 6 of Amendment No. 2.
Read in the reply
Summary, page 17
SEC asked (7)
Please revise to disclose all possible sources and extent of dilution that shareholders who elect not to redeem their shares may experience in connection with the business combination. Provide disclosure of the impact of each significant source of dilution, including the amount of equity held by founders, convertible securities, including warrants retained by redeeming shareholders, at each of the redemption levels
Rest of the question

detailed in your sensitivity analysis, including any needed assumptions.

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 5 and 6 of Amendment No. 2.
Read in the reply
Summary, page 17
SEC asked (8)
It appears that underwriting fees remain constant and are not adjusted based on redemptions. Revise your disclosure to disclose the effective underwriting fee on a percentage basis for shares at each redemption level presented in your sensitivity analysis related to dilution.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on page 26 of Amendment No. 2.
Read in the reply
Material Tax Considerations, page 114
SEC asked (9)
We note the merger agreement indicates that the merger will qualify as a reorganization under Section 368(a) of the Internal Revenue Code. Please discuss the tax consequences of the merger in the filing and whether you intend for the merger to qualify as a reorganization within the meaning of Section 368(a) of the Internal Revenue Code.
Rest of the question

To the extent you believe that the merger qualifies as a reorganization within Section 368(a) of the Internal Revenue Code, you must obtain a legal opinion supporting such a conclusion. Otherwise, disclose that it is uncertain whether the domestication will qualify as a tax-free reorganization and describe the potential consequences to shareholders, including a summary of the tax consequences if the merger fails to qualify as a 368(a) reorganization.

IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 13 and 115-120 of Amendment No. 2.
Read in the reply
Conflict of Interest, page 161
SEC asked (10)
Your charter waived the corporate opportunities doctrine. Please address this potential conflict of interest and whether it impacted your search for an acquisition target.
IONQ answered
In response to the Staff’s comment, the Company has revised the disclosure on pages 164 and 165 of Amendment No. 2.
Read in the reply
Note 10. Stock-Based Compensation, page F-22
SEC asked (11)
We have reviewed your response to prior comment 12. Please address the following items; • Your response indicates that on March 7, 2021, you signed the definitive merger agreement with dMY with a pre-money equity value of $1.275 billion and the fair value of IonQ's common stock was determined to be $31.71 per share.
Rest of the question

Further, your response states that on March 8, 2021, you announced the proposed business combination with a pre-money equity value for IonQ of $1.275 billion, which resulted in an implied fair value of the shares of IonQ common stock to be $41.30 per share. Please explain what occurred to result in the change in the fair value of the shares during this one day. • Given the final implied fair value of $41.30 on March 8, 2021, please explain in greater detail how you concluded your deemed fair value of shares on recent grant dates, for example, $30.61 on March 4, 2021 remains appropriate. We note your disclosure under the title, Reassessment of 2021 Awards, that "IonQ did not identify any significant events that occurred during the period between valuation dates that would have caused a material change in fair value."

IONQ answered
indicates that on March 7, 2021, you signed the definitive merger agreement with dMY with a pre-money equity value of $1.275 billion and the fair value of IonQ’s common stock was determined to be $31.71 per share. Further, your response states that on March 8, 2021, you announced the proposed business combination with a pre-money equity value for IonQ of $1.275 billion, which resulted in an implied fair value of the shares of IonQ common stock to be $41.30 per share.
Rest of the answer

Please explain what occurred to result in the change in the fair value of the shares during this one day.

Given the final implied fair value of $41.30 on March 8, 2021, please explain in greater detail how you concluded your deemed fair value of shares on recent grant dates, for example, $30.61 on March 4, 2021 remains appropriate. We note your disclosure under the title, Reassessment of 2021 Awards, that “IonQ did not identify any significant events that occurred during the period between valuation dates that would have caused a material change in fair value.”

Response: On March 7, 2021, IonQ and the Company signed a definitive merger agreement, which assigned a pre-money equity value of $1.275 billion to IonQ, and resulted in an implied per share fair value of $41.30, as determined by the estimated exchange ratio as of that date. The actual exchange ratio will vary based on the amount of net cash of IonQ, transaction costs and IonQ’s fully-diluted capitalization as of the effective date of the business combination.

The Company acknowledges the Staff’s comment and respectfully advises the Staff that when assessing the deemed fair value of the shares on recent grant dates, including on March 4, 2021, the signing of the definitive merger agreement was one input that was considered by IonQ’s board of directors and its third-party valuation specialist. In accordance with the American

Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the “Practice Guide”), IonQ determined the fair value of its common stock using a Probability-Weighted Expected Return Method (“PWERM”). The PWERM considers various market approach calculations depending upon the likelihood of various discrete future liquidity scenarios. In its March 8, 2021 valuation, IonQ considered two scenarios:

the consummation of the business combination with the Company (referred to as the “Transaction

Scenario”) in 2021; and

IonQ remaining a private company (referred to as a “Stay Private Scenario”) for another approximately 4.0 years.

The Transaction Scenario was based on IonQ’s pre-money equity value of $1.275 billion as contemplated by the business combination, and was weighted at 85% reflecting IonQ management’s best estimate of the likelihood of consummating the proposed business combination considering progress through the valuation date, as well as the risks that the business combination may not be completed. The Company and IonQ respectfully submit that it would be inconsistent with the fair value methodologies prescribed by the Practice Guide to weight the Transaction Scenario at 100% due to the inherent uncertainty in completing a business combination. The Company and IonQ respectfully further submit that the assignment of a 85% probability was reasonable under existing market conditions and the several conditions that must be met prior to the closing of the business combination, such as:

the receipt of the requisite vote at the special meeting of dMY stockholders;

market risks, including the market appetite for special purpose acquisition company transactions; and the receipt of regulatory approvals.

IonQ further applied a discount for lack of marketability (“DLOM”) of 9%. This DLOM incorporated IonQ’s best estimate the timing of the potential business combination to occur later in 2021.

Under the Stay Private Scenario, IonQ utilized the market approach using an adjusted back-solve method to determine IonQ’s enterprise value which consisted of using the October 2019 back-solve method valuation and adjusting for the increase in enterprise value based on the advancement of IonQ’s quantum computing technology between the intervening dates. After determining enterprise value, IonQ utilized the option pricing method to allocate its enterprise value to IonQ’s various classes of capital stock, including its common stock and applied a DLOM of 35%, given the significant time to liquidity of approximately 4.0 years.

Applying the PWERM to the two scenarios, IonQ arrived at a fair value of $31.71 per share.

Initial Reassessment of 2021 Awards

As noted in the Company’s prior response, as a result of the March 8, 2021 valuation discussed above, IonQ retrospectively assessed the fair value of IonQ’s common stock in connection with its 2021 awards using a linear interpolation and deemed fair values per share for financial accounting purposes ranging between $16.56 per share for the January 12, 2021 grants and

$30.61 per share for the March 4, 2021 grants. IonQ has not issued any additional option grants since the March 4, 2021 grants.

Significant changes between the December 2020 valuation and the March 8, 2021 valuation resulted from the increase in probability of the

Transaction Scenario from 25% to 85%. IonQ believes that the linear interpolation provides the most reasonable basis for the valuation of its common stock because IonQ did not identify any significant events that occurred during the period between valuation dates that would have caused a material change in fair value. Rather, the increase in probability of the Transaction Scenario resulted from the incremental progress that culminated in the approval of the definitive merger agreement by the

Company’s board of directors.

Revised Reassessment of 2021 Awards

IonQ believes that the process the IonQ board of directors used to determine the fair value of its common stock as of March 8, 2021 was appropriate and represented a reasonable estimate of the fair value of its common stock on such date. However, with the benefit of hindsight, IonQ has reconsidered certain inputs in such valuation. Specifically, the probability weighting assigned to the Transaction Scenario was increased from 85% to 95%, while the Stay Private Scenario was reduced from 15% to 5%. Further, the DLOM for the Transaction Scenario was reduced from 9% to 6%. IonQ believes both the initial and revised inputs are within a range of reasonableness, considering the inherent uncertainty in valuing equity securities of privately-held companies; however, the revised inputs are a better reflection of its expectations regarding the timing and likelihood of the proposed business combination. These changes resulted in a revised fair value of $36.32 per share as of

March 8, 2021.

IonQ has evaluated the impact to its financial statements of utilizing a fair value of $36.32 per share for the

March 8, 2021 valuation. As a result of performing linear interpolation using the revised fair value of $36.32 per share, the grant date fair values used for financial accounting purposes now range between $18.00 per share for the

January 12, 2021 grants and $34.99 per share for the March 4, 2021 grants. The impact to IonQ’s first quarter 2021 stock-based compensation expense is an increase of $117,000, and an increase in aggregate unrecognized stock-based compensation of $4.5 million as of March 31, 2021. The increase in stock-based compensation would increase total operating expenses for the three months ended March 31, 2021 by less than 2%, and is immaterial on both a quantitative and qualitative basis. The impact of the incremental increase in stock-based compensation expense (giving effect to the reassessed grant date fair values) will be recorded in the three-month period ended June 30, 2021.

Comparison to the Business Combination Implied Fair Value

As disclosed in IonQ’s investor presentation filed by the Company on a Current Report on Form 8-K on March 8, 2021, the IonQ equity value applies a range of 10.0x to 15.0x revenue multiple to IonQ’s 2026 estimated revenue to arrive at an implied future enterprise value range. This range was then discounted five years at a 20% discount rate to arrive at an implied discounted enterprise value range and an implied per share price of $41.30. The revised fair value of $36.32 per share as calculated in accordance with the Practice Guide reflects a modest 12% discount from the implied fair value of $41.30 per share, which IonQ and the Company respectfully submit is a reasonable discount to account for the risk of and timing of completion of the business combination. Therefore, the Company and IonQ respectfully submit that the reassessed value per share as calculated in accordance with the Practice Guide is reasonable and appropriate under U.S. GAAP.

****************************

We hope that the Company’s responses above adequately addresses the Staff’s comments. If the Staff has any questions or requires any additional information, please do not hesitate to contact Adam J. Brenneman at Cleary Gottlieb Steen & Hamilton LLP at (212) 225-2000.

Read in the reply
Notes to Condensed Financial Statements · Note 7. Share Based Compensation, page F-40
SEC asked
We note your discussion of your revised reassessment of the 2021 awards in response to prior comment 11. Please disclose the impact of the reassessment on current and future periods in the quarter ended June 30.
IONQ answered
The Company acknowledges the Staff’s comment and confirms that the Company will disclose the impact of its reassessment on current and future periods in the financial statements for the period ended June 30, 2021 and in Management’s Discussion and Analysis of Financial Condition and Results of Operation for the same period, which it expects to include on a Current Report on Form 8-K to be filed in connection with the closing of the Business

Combination.

The Company further advises the Staff that it is simultaneously filing Amendment No.
Rest of the answer

3 to reflect additional unrelated updates and exhibits.

****************************

We hope that the Company’s responses above adequately addresses the Staff’s comments. If the Staff has any questions or requires any additional information, please do not hesitate to contact Adam J. Brenneman at Cleary Gottlieb Steen & Hamilton LLP at (212) 225-2000.

Read in the reply

Also in this review: company letter, Aug 10, 2021, company letter, Oct 20, 2021

Letters without questions

Other letters

UPLOAD and CORRESP
5 other letters: notices that a filing will not be reviewed, requests to declare a registration effective, and the like
  • Mar 27, 2026 · IONQ: letter to the SEC · IonQ, Inc. · Registration Statement on Form S-4 · File No. 333-294511 · Request for...
  • Mar 24, 2026 · SEC: will not review the filing · IonQ, Inc. · Registration Statement on Form S-4 · Filed March 20, 2026 · File No. 333-294511
  • Nov 29, 2023 · IONQ: letter to the SEC · IonQ, Inc. · Registration Statement on Form S-3 · Filed November 9, 2023 · File No....
  • Nov 15, 2023 · SEC: will not review the filing · IonQ, Inc. · Registration Statement on Form S-3 · Filed November 9, 2023 · File No. 333-275444
  • Oct 13, 2021 · SEC: will not review the filing · IonQ, Inc. · Registration Statement on Form S-1 · Filed October 4, 2021 · File No. 333-260008

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 13 letters filed since 2021-04-27. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONQ/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.